3 Stocks Advancing The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 16 points (0.1%) at 16,733 as of Monday, June 2, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,394 issues advancing vs. 1,564 declining with 187 unchanged.

The Drugs industry currently sits down 1.4% versus the S&P 500, which is unchanged. Top gainers within the industry include NPS Pharmaceuticals ( NPSP), up 9.2%, and Teva Pharmaceutical Industries ( TEVA), up 2.6%. On the negative front, top decliners within the industry include Grifols ( GRFS), down 2.5%, Biogen Idec ( BIIB), down 0.8%, Sanofi ( SNY), down 0.7% and Abbott Laboratories ( ABT), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Allergan ( AGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Allergan is up $2.99 (1.8%) to $170.45 on heavy volume. Thus far, 4.9 million shares of Allergan exchanged hands as compared to its average daily volume of 4.4 million shares. The stock has ranged in price between $168.62-$171.65 after having opened the day at $169.20 as compared to the previous trading day's close of $167.46.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $47.2 billion and is part of the health care sector. Shares are up 50.8% year-to-date as of the close of trading on Friday. Currently there are 6 analysts who rate Allergan a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Johnson & Johnson ( JNJ) is up $0.52 (0.5%) to $101.98 on light volume. Thus far, 2.8 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.7 million shares. The stock has ranged in price between $101.01-$102.07 after having opened the day at $101.54 as compared to the previous trading day's close of $101.46.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $285.1 billion and is part of the health care sector. Shares are up 10.8% year-to-date as of the close of trading on Friday. Currently there are 8 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is up $0.16 (0.5%) to $29.79 on light volume. Thus far, 10.3 million shares of Pfizer exchanged hands as compared to its average daily volume of 30.7 million shares. The stock has ranged in price between $29.59-$29.80 after having opened the day at $29.59 as compared to the previous trading day's close of $29.63.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $188.8 billion and is part of the health care sector. Shares are down 3.3% year-to-date as of the close of trading on Friday. Currently there are 7 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists